Introduction {#Sec1}
============

The World Health Organisation defines myocarditis as an inflammatory disease of the myocardium diagnosed by established histological, immunological and immunohistochemical criteria \[[@CR1]\]. Myocardial involvement in presumed systemic viral infection is the most common aetiology, although it can result from a wide spectrum of infectious pathogens and non-infectious causes including systemic inflammatory conditions and toxins \[[@CR2], [@CR3]\].

Clinical presentation is often non-specific and heterogeneous, ranging from symptoms of chest pain, dyspnoea, fatigue or palpitations to brady- and tachy-arrhythmias, cardiogenic shock and sudden death \[[@CR2]\]. Peripheral markers of inflammation (e.g. c-reactive protein) and myocardial injury (e.g. troponin) lack sensitivity and specificity, and viral serology is unhelpful \[[@CR4]--[@CR6]\]. Invasive endomyocardial biopsy (EMB) is recommended in specific scenarios, such as "New-onset heart failure of 2 weeks duration associated with a normal-sized or dilated left ventricle and hemodynamic compromise (IB)" and "New-onset heart failure of 2 weeks to 3 months duration associated with a dilated left ventricle and new ventricular arrhythmias, second- or third-degree heart block, or failure to respond to usual care within 1 to 2 weeks (1B)", \[[@CR7]\] however, it is associated with a risk of complications (1--2%) and due to sampling error, transiency of myocardial injury and variation in histology interpretation, it also lacks accuracy \[[@CR2], [@CR8]--[@CR12]\]. In most centres it is rarely performed. As a result of these factors, the diagnosis of myocarditis is challenging, and has traditionally been made after other cardiac diseases have been excluded \[[@CR2]\].

Over the past decade, cardiac magnetic resonance (CMR) has changed this paradigm. The unique ability of multiparametric CMR to characterise myocardial tissue, and thus potentially detect the myocardial oedema, increased blood flow and capillary leakage, necrosis and subsequent fibrosis that occurs in myocarditis, coupled with the ability of CMR to detect subtle regional or global contractile dysfunction, means that CMR is now often able to provide a positive diagnosis of myocarditis. Indeed, CMR has provided pathophysiological insight into the nature of the myocardial injury in myocarditis.

This review will describe the diagnostic utility of CMR parameters across a range of myocarditic aetiologies. In this context, it is important to recognise that the evaluation of CMR, or indeed any diagnostic test, in myocarditis is limited by the lack of a good reference standard. Histological validation is challenging and imperfect, as described. As a result, many studies use a clinical diagnosis of myocarditis as the reference, however this is inherently limited. In addition, heterogeneous study designs and patient populations (e.g. acute versus chronic myocardial inflammation, definition of control groups), and the nature of CMR (differing magnetic field strengths, imaging sequences, measured parameters) makes comparisons between studies difficult.

Idiopathic (presumed viral) myocarditis {#Sec2}
=======================================

In North America and Europe, myocardial involvement in presumed systemic viral infection remains the most common aetiology of myocarditis \[[@CR2], [@CR13]--[@CR18]\].

T2 weighted imaging {#Sec3}
-------------------

T2 relaxation is directly proportional to tissue water content, and T2 weighted (T2w) imaging has been proposed to detect myocardial oedema \[[@CR3], [@CR19], [@CR20]\].

Table [1](#Tab1){ref-type="table"} summarises studies that have evaluated the diagnostic performance of T2w imaging, including the sequences employed, the populations studied and the reference standards \[[@CR21]--[@CR35]\]. Most studies analyse T2w images using an oedema ratio (ER), defined as the ratio of myocardial to skeletal muscle signal intensity (SI), with values above a set value considered pathological. However, the threshold varies across studies (1.8--2.2), is usually determined retrospectively and the technique is hampered by potential coexistence of myositis and a lack of skeletal muscle in the field of view \[[@CR21], [@CR35]\]. A minority of studies have used qualitative assessment, although a lack of 'healthy' myocardium for comparison in the context of global myocarditis is a limitation \[[@CR35]\].

Table 1T2w ImagingStudyField strengthSequenceValidationMyocarditis (n)Control (n)Acute versus chronic cardiac inflammationControl groupTest resultSensitivity (%)Specificity (%)Diagnostic accuracy (%)PPV (%)NPV (%)Laissy et al. Chest \[[@CR21]\]1 TT2w sequence with long TR/TEClinical207AcuteHealthy participantsQualitative451005910039Abdel-Aty et al. J Am Col Cardiol \[[@CR22]\]1.5 TT2w triple inversion recovery sequenceClinical2523AcuteHealthy participantsER cut off 1.98474797881Gutberlet et al. Radiology \[[@CR23]\]1.5 TT2w triple inversion recovery sequenceEMB4835ChronicOther diagnosesER cut off 26769687460Röttgen et al. Eur Radiol \[[@CR24]\]1.5 TT2w triple inversion recovery sequenceEMB8249AcuteNo inflammation on EMBER cut off 25857587341Voigt et al. Eur Radiol \[[@CR25]\]1.5 TT2w triple inversion recovery sequenceEMB1211ChronicNo inflammation on EMBER cut off 1.89282878590Lurz et al. JACC Cardiovasc Imaging [@CR26]1.5 TT2w triple inversion recovery sequenceEMB5317AcuteOther diagnosesER cut off 1.96465648537Lurz et al. JACC Cardiovasc Imaging \[[@CR26]\]^a^1.5 TT2w triple inversion recovery sequenceEMB3032ChronicOther diagnosesER cut off 1.94266545850Chu et al. Int J Cardiovasc Im \[[@CR27]\]1.5 TT2w triple inversion recovery sequenceClinical3510AcuteHealthy participantsQualitative691007610048Ferreira et al. JACC Cardiovasc Imaging \[[@CR28]\]1.5 TAcquisition for cardiac unified T2 oedema sequenceClinical5045AcuteHealthy participantsER cut off 2.26755617842Sramko et al. Am J Cardiol \[[@CR29]\]1.5 TT2w dark blood sequenceEMB1527ChronicIdiopathic DCMER cut off 1.91393645166Ferreira et al. J Cardiovasc Magn Reson \[[@CR30]\]1.5 TT2w triple inversion recovery sequenceClinical6050AcuteHealthy participantsER cut off 2.04886658158Radunski et al. JACC Cardiovasc Imaging \[[@CR31]\]1.5 TT2w triple inversion recovery sequenceClinical10421Mostly AcuteHealthy ParticipantsER cut off 2.27642708430Luetkens et al. Radiology \[[@CR32]\]3 TT2w triple inversion recovery sequenceClinical2442AcuteHealthy ParticipantsER cut off 2.097961685882Schwab et al. Rofo \[[@CR33]\]1.5 TT2w triple inversion recovery sequenceClinical4335AcuteHealthy participantsQualitative561007610065Hinojar et al. JACC Cardiovasc Imaging \[[@CR34]\]1.5 T / 3 TT2w triple inversion recovery sequenceClinical6140AcuteHealthy participantsQualitative/ER5694719555Luetkens et al. Eur H J Cardiovasc im \[[@CR35]\]1.5 TT2w triple inversion recovery sequenceClinical3450AcuteHealthy participantsER cut off 1.95094768573Pooled data6964946276677858Chronic inflammation only5576656963Acute inflammation only6376688057Healthy participants as control6479708161Other diagnoses as controls5869637354*DCM* dilated cardiomyopathy, *ER* oedema ratio, *EMB* endomyocardial biopsy, *NPV* negative predictive value, *PPV* positive predictive value, *TE* echo time, *TR* repeat time; *T2w* T2 weighted^a^One study examining two groups of patients with acute and chronic cardiac inflammation

The pooled weighted sensitivity, specificity and diagnostic accuracy of T2w for diagnosing acute myocarditis are 63, 76 and 68% respectively.

In the largest study (104 patients), in which a clinical diagnosis of myocarditis was used as the reference standard, Radunski et al. reported a modest diagnostic accuracy (70%) \[[@CR31]\]. Median interval between symptom onset and scan was 2 weeks, however the interquartile range was up to 7 weeks, by which time patients may have been in the convalescent stage. Indeed, the effect of delayed scan timing on T2w imaging sensitivity was investigated by Monney et al \[[@CR36]\] and Hinojar et al \[[@CR34]\], who found a higher prevalence of abnormal signal on T2w images when scanning within 2 weeks of symptom onset (81 and 56% respectively) compared to scanning performed later (11% at 39 days \[[@CR36]\] and 12% at 6 months \[[@CR34]\]). Other studies comparing acute and convalescent imaging have also shown that high T2 signal is a transient feature of inflammatory response \[[@CR36]--[@CR40]\]. In addition, abnormalities detectable on T2w imaging appear to vary according to clinical presentation, with a higher prevalence in the context of infarction-like symptoms (81% sensitivity) and much lower in the setting of heart failure or arrhythmias (sensitivity 28 and 27% respectively) \[[@CR41]\].

Early gadolinium enhancement {#Sec4}
----------------------------

Early gadolinium enhancement (EGE) exploits the phenomenon of regional vasodilatation, increased blood flow and capillary leakage present in an inflammatory process which results in increased contrast retention in the early washout period \[[@CR3]\].

Table [2](#Tab2){ref-type="table"} summarises studies that have evaluated the diagnostic performance of EGE imaging \[[@CR3], [@CR21]--[@CR27], [@CR29], [@CR31]--[@CR33], [@CR35], [@CR42]\]. Analysis of EGE images is performed using Myocardial Signal Enhancement, defined as myocardial SI post-contrast minus myocardial SI pre- contrast divided by myocardial SI pre- contrast, with values above 45--56% considered pathological \[[@CR21], [@CR29], [@CR31]\], or more commonly, the global relative enhancement (gRE),\[[@CR42]\] which is calculated as myocardial signal enhancement divided by skeletal muscle signal enhancement. Most studies use a gRE value of 4.0 as the threshold between healthy and abnormal myocardium \[[@CR22]--[@CR27], [@CR32]\]. Such analyses have similar disadvantages to the ER.

Table 2Early gadolinium enhancementStudyField strengthSequenceValidationMyocarditis (n)Control (n)Acute versus chronic cardiac inflammationControl groupTest resultSensitivity (%)Specificity (%)Diagnostic accuracy (%)PPV (%)NPV (%)Friedrich et al. Circulation \[[@CR3], [@CR42]\]1 TT1w spin echo sequenceClinical1918AcuteHealthy ParticipantsgRE8489868984Laissy et al. Chest \[[@CR3], [@CR21]\]1 TT1w sequence with short TR/TEClinical207AcuteHealthy ParticipantsMSE cut off 45%851008910070Abdel-Aty et al. J Am Col Cardiol \[[@CR22]\]1.5 TT1w spin echo sequenceClinical2523AcuteHealthy ParticipantsgRE cut off 4.08068757475Gutberlet et al. Radiology \[[@CR23]\]1.5 TT1w fast spin echo sequenceEMB4835ChronicOther diagnosesgRE cut off 4.06386738663Röttgen et al. Eur Radiol \[[@CR24]\]1.5 TT1w fast spin echo sequenceEMB8249AcuteNo inflammation on EMBgRE cut off 4.04974577843Voigt et al. Eur Radiol \[[@CR25]\]1.5 TT1w spin echo sequenceEMB1211ChronicNo inflammation on EMBgRE cut off 4.05864616458Lurz et al. JACC Cardiovasc Imaging \[[@CR26]\]^a^1.5 TT1w fast spin echo sequenceEMB5317AcuteOther diagnosesgRE cut off 4.07653708341Lurz et al. JACC Cardiovasc Imaging \[[@CR26]\]^a^1.5 TT1w fast spin echo sequenceEMB3032ChronicOther diagnosesgRE cut off 4.07321485140Chu et al. Int J Cardiovasc I \[[@CR27]\]1.5 TT1w turbo spin echo sequenceClinical3510AcuteHealthy ParticipantsgRE cut off 4.06390699641Sramko et al. Am J Cardiol \[[@CR29]\]1.5 TT1w turbo flash sequenceEMB1527ChronicIdiopathic DCMMSE cut off 45%4096768574Radunski et al. JACC Cardiovasc Imaging \[[@CR31]\]1.5 TT1w spin echo sequenceClinical10421Mostly AcuteHealthy ParticipantsMSE cut off 56%6371599131Luetkens et al. Radiology \[[@CR32]\]3 TT1w fast spin echo sequenceClinical2442AcuteHealthy ParticipantsgRE cut off 4.08342605377Schwab et al. Rofo \[[@CR33]\]1.5 TT1w fast spin echo sequenceClinical4335AcuteHealthy ParticipantsQualitative assessment5194719261Luetkens et al. Eur H J Cardiovasc im \[[@CR35]\]1.5 TT1w fast spin echo sequenceClinical3450AcuteHealthy ParticipantsgRE cut off 1.957762675880Pooled data5443776569677558Chronic inflammation only6266646564Acute inflammation only6670677856Healthy participants as control6970697760Other diagnoses as controls6167637255*DCM* dilated cardiomyopathy, *EMB* endomyocardial biopsy, *gRE* -- global relative enhancement, *MSE* myocardial signal enhancement, *NPV* negative predictive value, *PPV* positive predictive value, *TE* echo time, *TR* repeat time, *T1w* T1 weighted^a^One study examining two groups of patients with acute and chronic cardiac inflammation

The pooled weighted sensitivity, specificity and diagnostic accuracy of EGE for diagnosing acute myocarditis are 66, 70 and 67% respectively, with a wide range of diagnostic performances reported for both myocardial signal enhancement and gRE analysis techniques. Interestingly, Bohnen et al. found no statistical difference in gRE between heart failure patients with histologically confirmed inflammation and those without \[[@CR43]\].

Friedrich et al \[[@CR42], [@CR44]\] found the pattern of signal enhancement was localised within first week but subsequently became more diffuse. By day 14, gRE values stopped being significantly higher in the myocarditis group compared to the control group. Studies comparing EGE in acute and convalescent phases show a significant drop in gRE, from 4.1--8.5 during acute presentation to 2.4--4.4 at follow up (performed 3--28 months later) \[[@CR37]--[@CR40]\].

Late gadolinium enhancement {#Sec5}
---------------------------

Late gadolinium enhancement (LGE) was originally thought to demonstrate irreversible myocardial injury only, however several studies have demonstrated a temporal change in the extent of LGE in myocarditis, with LGE volume seen to decrease significantly over time (follow up scans performed between 1 and 18 months) \[[@CR3], [@CR36]--[@CR38], [@CR40], [@CR45]\]. Histological correlation has shown LGE is associated with active inflammation, with the extent of LGE corresponding to the severity of the inflammatory histopathological findings \[[@CR45], [@CR46]\]. It is likely that LGE in acute myocarditis represents both reversible and irreversible myocardial injury, but in the chronic phase represents residual focal fibrosis. See Fig. [1](#Fig1){ref-type="fig"}a for a representative example.

Fig. 1Patient with acute viral myocarditis. **a** Late enhancement imaging. Epicardial and mid-wall late enhancement (*green arrows*) in mid anterolateral and apical lateral segments. **b** T1 mapping, MOLLI sequence. Elevated T1 values in mid-wall and epicardial portion of basal---mid anterolateral and apical lateral segments (*green arrows*; T1 values in anterolateral wall: 1152 ms, T1 values in basal inferoseptum: 1031 ms). **c** T2 mapping, T2-prepared SFFP sequence. Elevated T2 values in epicardial portion of mid anterolateral and apical lateral segments (*green arrows*; T2 values in mid anterolateral segment: 66 ms, T2 values in basal inferoseptum: 47 ms)

Table [3](#Tab3){ref-type="table"} summarises studies that have evaluated the diagnostic performance of LGE imaging \[[@CR22]--[@CR27], [@CR29]--[@CR35], [@CR45], [@CR47]\]. The pooled weighted sensitivity, specificity and diagnostic accuracy of LGE for diagnosing acute myocarditis are 65, 95 and 75% respectively. The prevalence of LGE varies considerably across studies (27--95%), likely reflecting the heterogeneity of the populations studied and the timing of CMR \[[@CR22]--[@CR27], [@CR29]--[@CR36], [@CR40], [@CR45], [@CR47]--[@CR51]\].

Table 3Late gadolinium enhancementStudyField strengthSequenceValidationMyocarditis (n)Control (n)Acute versus chronic cardiac inflammationControl groupSensitivity (%)Specificity (%)Diagn accuracy (%)PPV (%)NPV (%)Abdel-Aty et al. J Am Col Cardiol \[[@CR22]\]1.5 TInversion-recovery gradient echo sequenceClinical2523AcuteHealthy participants44100717862Mahrholdt et al. Circulation \[[@CR45]\]1.5 TInversion-recovery gradient echo sequenceEMB10226AcuteNo inflammation on EMB8796899965Gutberlet et al. Radiology \[[@CR23]\]1.5 TInversion-recovery gradient echo sequenceEMB4835ChronicOther diagnoses2780496544Yilmaz et al. Heart \[[@CR47]\]1.5 TInversion-recovery gradient echo sequenceEMB4823AcuteNo inflammation on EMB3583518138Röttgen et al. Eur Radiol \[[@CR24]\]1.5 TInversion-recovery gradient echo sequenceEMB8249AcuteNo inflammation on EMB3188528439Voigt et al. Eur Radiol \[[@CR25]\]1.5 TInversion-recovery gradient echo sequenceEMB1211ChronicNo inflammation on EMB5845525350Lurz et al. JACC Cardiovasc Imaging \[[@CR26]\]^a^1.5 TInversion-recovery turbo gradient echo sequenceEMB5317AcuteOther diagnoses7465728744Lurz et al. JACC Cardiovasc Imaging \[[@CR26]\]^a^1.5 TInversion-recovery turbo gradient echo sequenceEMB3032ChronicOther diagnoses6135485144Chu et al. Int J Cardiovasc Im \[[@CR27]\]1.5 TInversion-recovery gradient echo sequenceClinical3510AcuteHealthy Participants7760738743Sramko et al. Am J Cardiol \[[@CR29]\]1.5 TPhase-sensitive inversion-recovery sequenceEMB1527ChronicIdiopathic DCM8744594686Ferreira et al. J Cardiovasc Magn Reson \[[@CR30]\]1.5 TPhase-sensitive inversion-recovery sequenceClinical6050AcuteHealthy Participants7297839867Radunski et al. JACC Cardiovasc Imaging \[[@CR31]\]1.5 TPhase-sensitive inversion-recovery sequenceClinical10421Mostly AcuteHealthy Participants611006810034Luetkens et al. Radiology \[[@CR32]\]3 TInversion-recovery gradient echo sequenceClinical2442AcuteHealthy Participants751009110088Schwab et al. Rofo \[[@CR33]\]1.5 TInversion-recovery turbo gradient echo sequenceClinical4335AcuteHealthy Participants861009210085Hinojar et al. JACC Cardiovasc Imaging \[[@CR34]\]1.5 T / 3 TInversion-recovery sequenceClinical6140AcuteHealthy Participants721008310079Luetkens et al. Eur H J Cardiovasc im \[[@CR35]\]1.5 TInversion-recovery gradient echo sequenceClinical3450AcuteHealthy Participants741008910085Pooled data7764916385728759Chronic inflammation only4953515151Acute inflammation only6595759659Healthy participants as control7098819869Other diagnoses as controls5770627748^a^One study examining two groups of patients with acute and chronic cardiac inflammation*DCM* dilated cardiomyopathy;*EMB* endomyocardial biopsy;*NPV* negative predictive value;*PPV* positive predictive value

While a number of studies have shown that LGE can involve any region of the LV (or the right ventricle), Mahrholdt et al.\[[@CR46]\] in seminal work, showed LGE is most commonly located in the lateral LV, typically originating from the epicardial quartile of the LV wall. Transmural lateral wall LGE, possibly reflecting very florid disease, is reported in a minority \[[@CR22], [@CR23], [@CR26], [@CR27], [@CR30], [@CR33], [@CR36], [@CR40], [@CR45], [@CR47], [@CR49]--[@CR53]\]. The distribution of LGE may be associated with the infecting pathogen, with parvovirus B19 found to be association with sub-epicardial lateral wall LGE, whereas human herpes virus 6 is associated with mid wall septal LGE \[[@CR45]\].

LGE imaging requires the presence of 'normal' myocardium as a reference, thus may not be sensitive to diffuse disease \[[@CR54]\].

Lake Louise criteria {#Sec6}
--------------------

In an effort to increase the diagnostic performance of CMR, the three tissue characterisation techniques discussed above (T2w imaging, EGE and LGE) were combined to form the Lake Louise Criteria (LLC). In the setting of clinically suspected myocarditis, abnormal findings on two of the three techniques were determined to be consistent with myocardial inflammation \[[@CR3]\].

Table [4](#Tab4){ref-type="table"} summarises studies that have evaluated the diagnostic performance of the LLC \[[@CR22], [@CR23], [@CR25]--[@CR27], [@CR31]--[@CR33], [@CR35]\]. The pooled weighted sensitivity, specificity and diagnostic accuracy of the LLC for diagnosing acute myocarditis are 80, 87 and 83% respectively, and as such the LLC demonstrate a better overall diagnostic performance than any of the individual CMR parameters. Similar to T2w imaging, LLC appears to have better diagnostic performance in "infarct-like" presentation (sensitivity of 80%) compared to heart failure or arrhythmias (sensitivity 57 and 40% respectively) \[[@CR41]\].

Table 4Lake Louise criteriaStudyField strengthValidationMyocarditis (n)Control (n)Acute versus chronic cardiac inflammationControl groupCMR sequencesSensitivity (%)Specificity (%)Diagnostic accuracy (%)PPV (%)NPV (%)Abdel-Aty et al. J Am Col Cardiol \[[@CR3], [@CR22]\]1.5 TClinical2523AcuteHealthy ParticipantsER, gRE, LGE7696869579Gutberlet et al. Radiology \[[@CR23]\]1.5 TEMB4835ChronicOther diagnosesER, gRE, LGE6389748863Voigt et al. Eur Radiol \[[@CR25]\]1.5 TEMB1211ChronicNo inflammation on EMBER, gRE, LGE7573747573Lurz et al. JACC Cardiovasc Imaging \[[@CR26]\]^a^1.5 TEMB5317AcuteOther diagnosesER, gRE, LGE8171799055Lurz et al. JACC Cardiovasc Imaging \[[@CR26]\]^a^1.5 TEMB3032ChronicOther diagnosesER, gRE, LGE6340515350Chu et al. Int J Cardiovasc Im \[[@CR27]\]1.5 TClinical3510AcuteHealthy ParticipantsQualitative T2w assessment, gRE, LGE77908096%53Radunski et al. JACC Cardiovasc Imaging \[[@CR31]\]1.5 TClinical10421Mostly AcuteHealthy ParticipantsER, MSE, LGE8457799041Luetkens et al. Radiology \[[@CR32]\]3 TClinical2442AcuteHealthy ParticipantsER, gRE, LGE9280857992Schwab et al. Rofo \[[@CR33]\]1.5 TClinical4335AcuteHealthy ParticipantsQualitative T2w assessment, qualitative EGE assessment, LGE671008210072Luetkens et al. Eur H J Cardiovasc im \[[@CR35]\]1.5 TClinical3450AcuteHealthy ParticipantsER, gRE, LGE8298929789Pooled data4082767781798670Chronic inflammation only6567666962Acute inflammation only8087839173Healthy participants as control8089849175Other diagnoses as controls7167697760*DCM* dilated cardiomyopathy, *ER* oedema ratio, *EMB* endomyocardial biopsy, *gRE* global relative enhancement, *MSE* myocardial signal enhancement, *NPV* negative predictive value, *PPV* positive predictive value, *T1w* T1 weighted, *T2w* T2 weighted^a^One study examining two groups of patients with acute and chronic cardiac inflammation

Parametric mapping {#Sec7}
------------------

In recent years, parametric mapping, which allows direct quantification of myocardial tissue magnetic parameters (primarily T1 and T2) has been increasingly applied in myocarditis. (Similar to T2, T1 relaxation times are sensitive to changes in myocardial water content and have been proposed to detect myocardial oedema). As well as being associated with potentially less observer variability, less artefact and allowing global myocardial assessment, native T1 and T2 mapping offer the significant advantage of not requiring contrast agent administration. See Fig. [1](#Fig1){ref-type="fig"}b, c for representative examples.

Table [5](#Tab5){ref-type="table"} summarises the studies that have evaluated the diagnostic performance of T2 and T1 mapping. The pooled weighted sensitivity, specificity and diagnostic accuracy of T2 mapping for diagnosing acute myocarditis are 70, 91 and 79% respectively \[[@CR31], [@CR35], [@CR43], [@CR51], [@CR55]\]. The pooled weighted sensitivity, specificity and diagnostic accuracy of T1 mapping are 82, 91 and 86% \[[@CR30]--[@CR32], [@CR34], [@CR35]\]. Thus the diagnostic performance of T2 mapping is comparable to that of the LLC, while the performance of T1 mapping may be superior.

Table 5Parametric mappingStudyField strengthSequenceValidationMyocarditis (n)Control (n)Acute versus chronic cardiac inflammationControl groupTest resultSensitivity (%)Specificity (%)Diagnostic accuracy (%)PPV (%)NPV (%)**T2 mapping**Thavendiranathan et al. Circ Cardiovasc Imaging \[[@CR51]\]1.5 TT2p-SFFPClinical2030AcuteHealthy participantsT2 cut off 59 ms9497969596Radunski et al. JACC Cardiovasc Imaging \[[@CR31]\]1.5 TT2 multiecho sequenceClinical8721Mostly AcuteHealthy participantsT2 cut off 61 ms5789639535Bohnen et al. Circ Cardiovasc Imaging \[[@CR43]\]1.5 THybrid gradient and spin-echo multiecho sequenceEMB1615ChronicNo inflammation on EMBT2 cut off 60 ms9460787190Baessler et al. J Cardiovasc Magn Reson \[[@CR55]\]1.5 TGraSELLC3130AcuteHealthy participantsmax T2 68 ms/madSD 0.228183828381Luetkens et al. Eur H J Cardiovasc Im \[[@CR35]\]1.5 TGraSEClinical3450AcuteHealthy participantsT2 cut off 59.9 ms7992878787Pooled data1881467287798871Chronic inflammation only9460787190Acute inflammation only7091799170Healthy participants as control7091799170Other diagnoses as controls9460787190**T1 mapping**Ferreira et al. J Cardiovasc Magn Reson \[[@CR30]\]1.5 TShMOLLIClinical6050AcuteHealthy participantsT1 cut off 990 ms9088899088Luetkens et al. Radiology \[[@CR32]\]3 TMOLLIClinical2442AcuteHealthy participantsT1 cut off 1140 ms9291918595Radunski et al. JACC Cardiovasc Imaging \[[@CR31]\]1.5 TMOLLIClinical10421Mostly AcuteHealthy participantsT1 cut off 1074 ms6490689734Hinojar et al. JACC Cardiovasc Imaging \[[@CR34]\]1.5 T / 3 TMOLLIClinical6140AcuteHealthy participantsT1 cut off 992 ms on 1.5 T, 1098 ms on 3 T981009910099Luetkens et al. Eur H J Cardiovasc im \[[@CR35]\]^a^1.5 TMOLLIClinical3450AcuteHealthy participantsT1 cut off 1000 ms8596929490Luetkens et al. Eur H J Cardiovasc im \[[@CR35]\]^a^1.5 TShMOLLIClinical3450AcuteHealthy participantsT1 cut off 852 ms8884867991Pooled data3172538291869281**ECV**Luetkens et al. Radiology \[[@CR32]\]3 TMOLLIClinical2442AcuteHealthy participantsECV cut off 26%6781766781Radunski et al. JACC Cardiovasc Imaging \[[@CR31]\]1.5 TMOLLIClinical10421Mostly AcuteHealthy participantsECV cut off 29%7390769740Luetkens et al. Eur H J Cardiovasc im \[[@CR35]\]^a^1.5 TMOLLIClinical3450AcuteHealthy participantsECV cut off 29%7076746779Luetkens et al. Eur H J Cardiovasc im \[[@CR35]\]^a^1.5 TShMOLLIClinical3450AcuteHealthy participantsECV cut off 30%5792788375Pooled data1961636984768469*DCM* dilated cardiomyopathy;*EMB* endomyocardial biopsy;*GraSE* Gradient spin echo T2 sequence;*LLC* Lake Louise Criteria;*MOLLI* Modified Look-Locker inversion recovery sequence;*NPV* negative predictive value;*PPV* positive predictive value;*ShMOLLI* Shortened modified Look-Locker inversion recovery sequence;*T2p-SFFP* T2 prepared steady-state free precession sequence^a^Two seprate T1 mapping sequences employed in one study: MOLLI and ShMOLLI

Luetkens et al. compared the diagnostic performance of CMR parameters in two studies, albeit in relatively small populations (24 and 34 patients with myocarditis respectively), and demonstrated similar findings. In the first study, which did not include T2 mapping \[[@CR32]\], native T1 mapping was associated with the highest diagnostic performance (area under the curve, AUC 0.94), followed by LGE (AUC 0.9), LLC (AUC 0.86), ER (AUC 0.79) and gRE (AUC 0.63). In the second study, which included T2 mapping,\[[@CR35]\], the performance of native T1 mapping (AUC 0.92--0.95) and T2 mapping (AUC 0.92) was very similar. Combining T1 mapping with LGE (diagnostic accuracy 91--96%) \[[@CR30], [@CR32], [@CR34], [@CR35]\] or T2 mapping and LGE (diagnostic accuracy 96%) \[[@CR35]\] may improve diagnostic performance further.

Nevertheless, there are a number of areas which require further investigation. Only one study has compared T1 and T2 mapping with histological findings in myocarditis. Relaxation time thresholds for diagnosing myocarditis have generally been determined retrospectively. T1 relaxation time diagnostic thresholds vary considerably between studies (852--1074 ms at 1.5 T). T2 relaxation time diagnostic thresholds are generally much more consistent (approximately 60 ms), however they overlap considerably with published normal ranges (up to 65 ms) \[[@CR51], [@CR56]--[@CR66]\]. A prospective, multicentre, multivendor trial with predetermined diagnostic thresholds is required to determine the clinical diagnostic utility of mapping with quantitative analysis before this technique can enter clinical practice.

Other noteworthy findings include those of Hinojar et al. who showed elevated T1 values (compared to healthy controls) persisted for up to 4--8 months post initial presentation \[[@CR34]\]. Bohnen et al. found no difference in T1 values in patients with heart failure and histologically confirmed inflammation compared to patients with heart failure and no evidence of inflammation on histology \[[@CR43]\]. This may reflect the fact that native T1 is determined by a number of factors other than inflammation (e.g. fibrosis).

Only three studies have examined the diagnostic utility of ECV in myocarditis, with varying results (Table [5](#Tab5){ref-type="table"}) \[[@CR31], [@CR32], [@CR35]\].

Acute cardiac allograft rejection {#Sec8}
=================================

Acute cardiac allograft rejection (ACAR) is a leading cause of death in the first year post heart transplant, however clinical features are unreliable. Routine screening is therefore performed in order to detect ACAR and hence augment immunosuppressive therapy, at an earlier stage, with the aim of preventing progression to more severe disease \[[@CR67], [@CR68]\]. Histological analysis of myocardial tissue obtained at EMB remains the gold standard for ACAR surveillance however it is associated with a number of limitations. CMR is a potentially attractive screening modality.

In one of the largest human studies, which included 68 patients undergoing 123 CMR scans, T2 relaxation time was significantly higher in grade 2 ACAR (57 ± 5 ms) compared with grade 0 or 1 (50 ± 5 ms and 51 ± 8 ms, respectively); and in grade 3 (65 ± 8 ms) compared with grade 2 \[[@CR69]\]. A T2 relaxation time of ≥56 ms, determined retrospectively, had a high NPV (97%) for detecting significant ACAR (≥grade 2). More recently in a study of approximately 50 patients undergoing 68 CMR scans, Usman et al. found myocardial T2 was significantly higher in the ACAR group (including 4 cases of \>grade 2R ACAR, two cases of antibody-mediated rejection and two cases where ACAR treatment was started on the basis of high clinical suspicion alone) compared to the non-ACAR group \[[@CR70]\]. A T2 of 56.4 ms yielded a sensitivity and specificity of 86.5 and 94.6% respectively. However, both studies specifically selected patients who were known to have/suspected of having ACAR. Furthermore, patients were a scanned at a substantial time post-transplant (Marie et al. up to 6 years, Usman et al. up to 2 years), thus missing the window in which early detection of ACAR is thought to be most useful, indeed the benefit of routine screening later than one year post-transplant is subject to debate.

In a study of 22 patients undergoing 88 CMR scans over the first 5 months post-transplant, Miller et al. found myocardial T1 and T2 were not significantly higher in grade 2R ACAR compared to grades 0R-1R \[[@CR71]\]. However the study did demonstrate significant improvements in markers of LV structure and contractility, native T1, T2 and ECV and microvascular function over the period studied, providing insight into the myocardial injury associated with transplantation, and its recovery.

It may be that CMR parameters become more useful for detecting ACAR as time from transplantation increases and the transplant-related myocardial injury subsides. The paradox however is that while non-invasive approaches to ACAR surveillance may become more discriminatory as time from transplantation increases, the benefit of the early detection of ACAR diminishes \[[@CR71]\].

Sarcoidosis {#Sec9}
===========

Sarcoidosis is a multi-organ systemic inflammatory disorder characterized by the formation of non-caseating granulomas \[[@CR72]\]. Autopsy studies suggest cardiac sarcoidosis is a major cause for sarcoid-related mortality, however pre-mortem diagnosis of cardiac sarcoid is challenging \[[@CR72], [@CR73]\]. Endomyocardial biopsy and clinical diagnostic criteria \[[@CR74]\] are limited \[[@CR75]\].

Smedema et al. \[[@CR76]\] found LGE in all patients (n = 12) meeting clinical criteria for cardiac sarcoid, and in a further 17% who did not meet the criteria. Patel et al. \[[@CR77]\] showed CMR identified twice as many patients (n = 21) with evidence of myocardial involvement as clinical evaluation, which included 12-lead ECG and at last one non-CMR cardiac investigation (echocardiography, radionuclide scintigraphy or cardiac catheterisation).

Regional and mural LGE distribution in cardiac sarcoid is markedly heterogeneous. LGE has been demonstrated in all LV and RV regions, albeit with some predilection to basal septal regions \[[@CR76]--[@CR80]\]. Subendocardial, mid wall, epicardial and transmural patterns have been described \[[@CR76]--[@CR80]\]. Using T2 mapping, Crouser et al. \[[@CR81]\] found significantly higher myocardial T2 values amongst 50 consecutive patients investigated for cardiac sarcoid compared to healthy controls. T2 cut off of 59 ms achieved sensitivity of 54% and specificity of 100%.

^18^F-fluoro-2-deoxyglucose positron emission tomography (^18^F-FDG PET; a marker of active inflammation) studies have provided insight into the CMR findings \[[@CR82], [@CR83]\]. T2w signal and LGE have been demonstrated to correspond to regions taking up ^18^F-FDG, with reduced uptake following corticosteroids, indicating active inflammation. However, LGE is also found in regions without ^18^F-FDG uptake, indicating fibrotic lesions. Thus T2w signal may reflect active inflammation, whereas LGE may reflect either active inflammation or fibrosis.

The presence of LGE is associated with a higher rate of sudden cardiac death (SCD) and ventricular tachyarrhythmia, although this requires further assessment in larger studies \[[@CR77]--[@CR79], [@CR84]\].

Systemic lupus erythematous {#Sec10}
===========================

Systemic lupus erythematous (SLE) is a multisystem inflammatory disorder \[[@CR85]\].

Cardiovascular involvement represents a significant cause of morbidity and mortality \[[@CR86]\]. SLE associated myocarditis was shown to shorten the survival and is more common amongst patients with higher disease activity \[[@CR87]\]. There is also a discrepancy between the number of myocarditis cases detected on autopsy and clinical diagnoses, suggesting common subclinical cardiac involvement \[[@CR88], [@CR89]\]. There is considerable interest in the accurate detection of myocardial involvement in SLE, and other rheumatological conditions, as it may potentially guide therapy aimed at reducing adverse cardiovascular outcomes.

A small study by Singh et al. \[[@CR90]\] showed that T2 relaxation times were higher in six patients with active SLE compared to five with lower disease activity and five healthy controls (T2 values of 82, 64 and 65 ms respectively). Similarly, Abdel-Aty et al. \[[@CR88]\] showed that both ER and gRE were significantly higher in patients with active disease, both correlated to disease activity and ER significantly decreased with clinical improvement.

Mavrogeni et al. \[[@CR89]\] compared a group of twenty-five patients with active SLE and suspected cardiac involvement with fifty patients suspected of having viral myocarditis showing no statistical difference in ER and EGE, potentially suggesting similar myocardial pathological processes in both conditions.

Puntmann et al. \[[@CR91]\] showed that T1 and ECV values were significantly higher among thirty-three SLE patients in clinical remission compared to twenty-one healthy controls (T1 1152 ± 46 vs. 1056 ± 27 ms, p \< 0.001; ECV 30 ± 6% versus 26 ± 5%, p = 0.007). A challenge for the CMR community is to decipher whether such findings represent active inflammation or chronic fibrosis, or indeed both. The authors did not perform T2 mapping, however, ER did not differ between groups, potentially suggesting the T1 and ECV findings may represent fibrosis. Conversely, Zhang et al. \[[@CR92]\] demonstrated higher T2 values in twenty-four SLE patients with low disease activity compared to twelve healthy controls (58.2 ± 5.6 vs. 52.8 ± 4.4 ms), which the authors suggested may represent ongoing myocardial inflammation.

LGE may be less prevalent in SLE. Zhang et al. \[[@CR92]\] observed no late enhancement amongst twenty-four SLE patients while Mavrogeni et al. \[[@CR89]\] found significantly less LGE amongst patients with active SLE compared to viral myocarditis (LGE volume 3.5 ± 5.5 vs. 8 ± 4.4%, p \< 0.001), possibly reflecting a more diffuse nature of myocardial involvement.

Rheumatoid arthritis {#Sec11}
====================

Rheumatoid arthritis (RA) is a chronic autoimmune disease \[[@CR93]\]. Cardiovascular involvement is common, manifesting as coronary artery disease, myocardial inflammation and fibrosis, and is responsible for 40--80% of premature deaths \[[@CR94]--[@CR97]\].

Kobayashi et al. \[[@CR98]\] examined eighteen RA patients without a previous history of cardiovascular conditions, finding LGE in almost 40% of patients, with a mostly non-ischaemic distribution. The presence of LGE was correlated to higher disease activity scores (DAS28 4.77 vs. 3.44, p = 0.011).

Mavrogeni et al. \[[@CR99]\] used T2w imaging, EGE and LGE to compare two groups of RA patients in remission: twenty with and twenty without recent onset cardiac symptoms. 10% of patients with symptoms had evidence of myocardial infarction with a typical ischaemic LGE pattern and 65% displayed evidence of myocarditis as defined by LLC. Over three quarters of those diagnosed with myocarditis experienced an RA relapse within 6 weeks, possibly suggesting more active disease.

Ntusi et al. \[[@CR100]\] found LGE to be present in almost half of twenty-eight examined RA patients with a mostly non-ischaemic, mid wall pattern. In addition, 5% of patients were diagnosed with silent myocardial infarction based on the presence of subendocardial LGE and confirmed by coronary angiography. There was no difference in global ER between RA patients and controls, however, RA patients had more areas of elevated ER (ER \> 1.9, median 10 vs. 0% amongst controls) suggesting the presence of focal myocardial oedema. Finally, global T1 values and ECV were significantly higher in the RA group (T1 973 ± 27 vs. 961 ± 18 ms, p = 0.03; ECV 30.3 ± 3.4 vs. 27.9 ± 2%, p \< 0.001). Although, in keeping with the findings in SLE, it is not clear to what extent these findings represent active inflammation or fibrosis and the magnitude of the difference in global T1, whilst statistically significant, were small.

It is clear from these CMR studies that subclinical cardiac involvement is common. CMR parameters have the potential to risk stratify and guide therapy in RA, although further work is required to define the nature of the CMR findings in RA and their accuracy and reproducibility in this population.

Systemic sclerosis {#Sec12}
==================

Systemic Sclerosis (SSC) is an autoimmune connective tissue disorder characterised by multi-organ fibrosis \[[@CR101]\]. Cardiac involvement in SSC is estimated at 15--35% \[[@CR101]\] and includes myocardial fibrosis, myocarditis, dilated cardiomyopathy, premature coronary artery disease, conduction abnormalities, valvular and pericardial disease \[[@CR102]\]. Myocardial pathologies are often subclinical with higher prevalence on autopsy studies \[[@CR103]\]. Overt cardiac disease is associated with poor prognosis, with a reported 70% mortality at 5 years \[[@CR104]\].

A number of studies have evaluated LGE in SSC patients, demonstrating a prevalence of LGE of between 4 and 66% \[[@CR105]--[@CR114]\]. LGE prevalence and distribution does not seem to differ between limited and diffuse cutaneous forms of SSC \[[@CR105], [@CR106], [@CR108], [@CR113]\]. Both non-ischaemic and ischaemic patterns of LGE are described \[[@CR105]--[@CR112]\] It is not clear whether the non-ischaemic LGE represents inflammation or fibrosis. Microvascular dysfunction is a prominent feature of SSC and diffuse myocardial ischaemia evident on perfusion imaging may be part of the pathophysiological process \[[@CR107], [@CR113]\].

In a study by Hachulla et al. \[[@CR106]\] fifty-two SSC patients without prior cardiac disease were assessed by multiparametric CMR. Qualitative T2w signal was increased in 12% of participants. Ntusi et al. \[[@CR110]\] study found nineteen SCC patients to have a significantly greater extent of high gRE values compared to twenty healthy controls \[[@CR110]\]. There was no difference between limited and diffuse cutaneous SSC \[[@CR106], [@CR110]\].

T1 mapping and ECV values were also shown to be higher in SSC patients without past cardiovascular involvement. In previously mentioned study by Ntusi et al. \[[@CR110]\], SSC participants had mean T1 values of 1007 ± 29 ms and ECV of 35.4 ± 4.8% compared to T1 of 958 ± 20 ms (p \< 0.001) and ECV of 27.6 ± 2.5% (p \< 0.001) amongst controls. Two further studies confirmed higher ECV in SSC patients compared to healthy controls: Barison et al. \[[@CR109]\] (30 SSC patients, ECV 30 ± 4% vs. 28 ± 4%, p = 0.03) and Thuny et al. \[[@CR115]\] (33 SSC patients, median ECV 30%, range 28--31.9% vs. 26.8%, range 25.4--29.1%, p = 0.001).

Conclusions {#Sec13}
===========

By providing a 'positive' diagnostic test, CMR has changed the management of suspected viral myocarditis and has provided new insight into myocardial involvement in systemic inflammatory conditions. Thus CMR has opened a window for potential therapeutic targets. Parametric mapping appears to offer advantages over more conventional CMR techniques. However, multicentre, multivendor clinical trials are required to fully establish the clinical utility of CMR in myocarditis, and, in particular, quantitative mapping analysis.
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